Greg Mossinghoff

Greg Mossinghoff has a diverse work experience in the pharmaceutical industry spanning over three decades. Greg co-founded Tavros Therapeutics in 2019, where they currently serve as the Co-Founder and Chief Business Officer. Prior to this, from 2018 to 2019, they held the position of Chief Business Officer at Symberix.

Before joining Symberix, Greg co-founded Zoion Pharma Inc. in 2010 and held the role of Executive Vice President and Chief Business Officer. From 2014 to 2018, they served as the Chief Business Officer at G1 Therapeutics, Inc.

Greg has also held leadership positions in other companies, including Integrated Oncology Solutions, Inc., where they were the President and CEO from 2006 to 2010. From 1998 to 2005, they were the President and CBO at Inspire Pharmaceuticals.

Greg Mossinghoff began their career with Roche and GlaxoWellcome, where they worked in various global and domestic US positions from 1988 to 1998.

Greg Mossinghoff attended the University of Virginia from 1979 to 1983, where they earned a Bachelor of Arts degree in Economics. Greg then went on to pursue a Master of Business Administration degree in Finance at George Mason University, which they obtained from 1983 to 1986.